Laparoscopic Heller Myotomy for Achalasia: Procedure, Outcomes and Alternatives — Cost, Top Hospitals & Success Rates | MyMedicPlus

Laparoscopic Heller myotomy (LHM), also called laparoscopic cardiomyotomy, is the surgical treatment of choice for achalasia — a primary oesophageal motility disorder characterised by failure of the lower oesophageal sphincter (LES) to relax during swallowing combined with absent or disordered peristalsis in the oesophageal body. Achalasia affects approximately 1 in 100,000 people per year and carries a lifetime prevalence of 10 per 100,000 population.

The pathophysiology of achalasia involves selective loss of inhibitory neurons (nitric oxide- and VIP-producing) in the myenteric plexus of the oesophagus, resulting in elevated resting LES pressure, impaired LES relaxation, and absent oesophageal peristalsis. The precise aetiology remains unclear; autoimmune, viral (HSV-1), and genetic factors have been implicated.

First described by Heller in 1913 as an open procedure, the operation was adapted for laparoscopy in 1991 by Pellegrini and colleagues. The minimally invasive approach rapidly became the dominant technique due to equivalent efficacy with lower morbidity, shorter hospital stay, and faster recovery compared to open surgery. The procedure involves division (myotomy) of the circular and longitudinal muscle fibres of the distal oesophagus and proximal stomach at the gastro-oesophageal junction, relieving the functional obstruction.

LHM is now evaluated alongside two other established therapies — per-oral endoscopic myotomy (POEM) and pneumatic dilation (PD) — which together define the modern therapeutic landscape for achalasia. The choice between these approaches depends on achalasia subtype, patient age and fitness, presence of oesophageal dilation (sigmoid achalasia), prior therapy, and local expertise.

Laparoscopic Heller myotomy is indicated primarily for achalasia, which is classified by high-resolution manometry (HRM) according to the Chicago Classification version 4.0 (CCv4.0, 2021):

• Type I Achalasia (Classic Achalasia): Complete absence of contractility in the oesophageal body with 100% failed peristalsis, with mean integrated relaxation pressure (IRP) above the upper limit of normal. LES does not relax adequately. Barium swallow demonstrates a smooth, tapered narrowing at the LES with a characteristic "bird's beak" appearance and proximal oesophageal dilation. Type I has the poorest response to all therapies but still achieves reasonable results with LHM or POEM.
• Type II Achalasia (Achalasia with Oesophageal Compression): Elevated IRP with 100% failed peristalsis and pan-oesophageal pressurisation in ≥20% of swallows. This subtype has the best prognosis and the highest response rates to all modalities — success rates of 90–95% are reported. Type II responds well to LHM, POEM, and pneumatic dilation.
• Type III Achalasia (Spastic Achalasia): Elevated IRP with premature (spastic) contractions in ≥20% of swallows. This is the most challenging subtype, with lower response rates to PD and LHM. POEM has an advantage over LHM in Type III achalasia because the endoscopic myotomy can extend proximally to address the spastic segment (typically 10–14 cm oesophageal myotomy vs 6 cm in LHM).
• Sigmoid (End-Stage) Achalasia: Long-standing untreated achalasia results in a sigmoid, tortuous, massively dilated oesophagus (>6 cm in diameter on barium swallow or CT). Surgical options include LHM (with variable success) or, in refractory cases, oesophagectomy. POEM can also be attempted in expert hands.

The Eckardt score is the validated symptom assessment tool for achalasia, scoring dysphagia, regurgitation, retrosternal pain, and weight loss (each 0–3, maximum 12). Treatment success is defined as Eckardt score ≤3 at follow-up. A baseline Eckardt score ≥3 is the standard threshold for active intervention.

Patient selection for LHM involves confirming the diagnosis of achalasia and determining whether surgical myotomy is preferable to endoscopic alternatives.

Diagnostic Workup: HRM (Chicago Classification v4.0) is mandatory to classify achalasia subtype and exclude other causes of dysphagia (pseudo-achalasia secondary to malignancy must be excluded by endoscopy and CT). Barium swallow demonstrates the "bird's beak" tapering at the LES and assesses oesophageal dilation and sigmoid morphology. Upper endoscopy excludes malignancy at the cardia and identifies peptic strictures or candida oesophagitis from stasis.

Candidate Assessment for LHM: LHM is appropriate for patients with confirmed achalasia and Eckardt score ≥3 who are fit for general anaesthesia and laparoscopic surgery. It is particularly well suited to patients with Type I or II achalasia who have not undergone prior myotomy, patients with sigmoid achalasia who require the wider exposure offered by laparoscopy, and patients with a preference to avoid endoscopic techniques. LHM is preferred over POEM when the goal is to minimise post-procedural gastro-oesophageal reflux disease (GERD), as an antireflux fundoplication (Dor or Toupet) is routinely added at laparoscopy.

Contraindications and Special Situations: Prior POEM or PD does not preclude LHM, though adhesions and mucosal changes increase technical difficulty. Elderly or frail patients with high anaesthetic risk may be better served by botulinum toxin injection (temporary, 6-month effect) or repeated PD as less invasive options. Patients with end-stage sigmoid achalasia should be assessed for oesophagectomy candidacy if LHM or POEM fails.

Pre-operative Assessment: All patients require nutritional assessment (malnutrition is common in long-standing achalasia), pulmonary assessment (aspiration pneumonia risk), and review of prior endoscopic procedures. Ambulatory pH monitoring before and after therapy characterises baseline reflux; post-operative pH studies confirm adequacy of the fundoplication.

Laparoscopic Heller Myotomy (LHM) Technique: The procedure is performed under general anaesthesia in the lithotomy or split-leg position. Five trocar ports are placed. The gastro-oesophageal junction is mobilised by dividing the hepatogastric ligament and phreno-oesophageal membrane. The anterior vagus nerve is preserved. The myotomy is performed on the anterior aspect of the oesophagus, beginning 3–4 cm above the GEJ and extending 6 cm onto the oesophagus plus 2.5–3 cm onto the gastric cardia (total 8–9 cm). The muscle fibres are divided down to the submucosa using hook cautery, ultrasonic dissector, or fine scissors. Mucosal integrity is confirmed intraoperatively by insufflation under saline irrigation or by intraoperative endoscopy.

Antireflux Fundoplication: Because LHM abolishes the natural anti-reflux barrier of the LES, a partial fundoplication is routinely added to prevent post-operative GERD (incidence ~30–50% without fundoplication). The two standard options are: Dor fundoplication (anterior 180-degree wrap — covers the myotomy site and protects against mucosal perforation) and Toupet fundoplication (posterior 270-degree wrap — provides better exposure of the myotomy edges and may offer superior reflux control). Both are equivalent in overall symptom outcomes. The Dor technique is more commonly used when mucosal integrity is uncertain.

Per-Oral Endoscopic Myotomy (POEM): An endoscopic alternative in which the myotomy is performed through a submucosal tunnel created via the oesophageal mucosa. The iPoEM International RCT demonstrated non-inferiority of POEM versus LHM at 2 years (success 83% vs 81%). POEM achieves a longer myotomy (10–14 cm oesophageal + 2–3 cm gastric), has advantages in Type III achalasia, and avoids abdominal surgery. However, POEM carries a higher rate of post-procedural GERD (approximately 40–57% on 24-hour pH monitoring) compared to LHM + fundoplication (~15–20%).

Endoscopic Pneumatic Dilation (PD): Fluoroscopy-guided dilation of the LES using 30–35–40 mm balloons (Rigiflex). A multicentre European RCT showed POEM and PD have equivalent success at 2 years (POEM 90% vs PD 87%; Patti et al., Lancet Gastroenterol 2021). PD is performed in repeated sessions and achieves success rates of 75–90% over 5 years. Perforation risk is approximately 1–3%.

Botulinum Toxin Injection: Endoscopic injection of 80–100 units of botulinum toxin A into the LES achieves clinical remission in approximately 60–70% of patients at 3 months, with efficacy declining to 30–40% at 12 months. It is reserved for elderly patients (>70 years), those with significant comorbidities precluding definitive therapy, or as a bridge to surgery in malnourished patients requiring nutritional rehabilitation.

Laparoscopic Heller myotomy delivers durable symptom relief with a favourable safety profile compared to open surgery. Key outcome data include:

Clinical Success Rates: LHM achieves short-term success (Eckardt score ≤3) in 85–95% of patients across published series. Long-term success (5-year data) is 80–85%, declining to approximately 70% at 10 years as LES fibrosis or symptom recurrence occurs. Type II achalasia has the best outcomes (90–95% success), followed by Type I (70–85%) and Type III (55–75%).

Comparison with POEM: The iPoEM international RCT (Ponds et al., Lancet 2019) comparing POEM versus LHM + Dor fundoplication showed equivalent procedural success at 24 months (POEM 83.0% vs LHM 81.7%, p=0.007 for non-inferiority). POEM had higher oesophagitis rates (41.1% vs 12.7%, p<0.001) and abnormal acid exposure (57.4% vs 20.3%). LHM with fundoplication was superior at protecting against reflux-related complications.

Dysphagia Relief: Postoperative dysphagia scores (Eckardt dysphagia subscale) fall from a mean of 2.5–3.0 pre-operatively to 0.3–0.7 at 12 months. Regurgitation and retrosternal pain also improve significantly. Weight gain is documented in malnourished patients.

Quality of Life: Multiple studies using validated tools (SF-36, EQ-5D, GIQLI) demonstrate significant improvement in quality of life following LHM. The laparoscopic approach is associated with 2–3 day hospital stay, rapid return to full activity at 2–3 weeks, and minimal wound morbidity compared to open myotomy (7–10 days stay, 6–8 weeks recovery).

Durability: At 10-year follow-up, approximately 65–75% of patients who underwent LHM remain in clinical remission without need for repeat intervention. Predictors of good long-term outcomes include Type II achalasia, moderate oesophageal dilation (<4 cm), younger age, and achieving complete myotomy extending onto the gastric cardia.

LHM is a safe procedure in experienced hands, but carries specific intraoperative and postoperative risks that must be discussed with patients during consent.

Intraoperative Complications: Oesophageal mucosal perforation is the most important intraoperative complication, occurring in approximately 5–10% of cases in high-volume series. Most perforations are recognised and repaired primarily at the time of surgery with excellent outcomes; unrecognised perforation carries significant risk of mediastinitis. Bleeding is uncommon (<1% requiring conversion). Conversion to open surgery occurs in 1–3% of cases, usually for bleeding, mucosal injury, or poor visualisation.

Postoperative GERD: Without fundoplication, approximately 30–50% of patients develop pathological acid reflux after LHM (the myotomy abolishes the anti-reflux function of the LES). With Dor or Toupet fundoplication, the incidence falls to 15–25% on 24-hour pH monitoring. Clinical GERD (symptomatic heartburn) occurs in 10–15%. Long-term PPI therapy may be required. Barrett's oesophagus has been reported in patients with long-standing post-myotomy reflux and requires surveillance endoscopy every 3–5 years.

Persistent or Recurrent Dysphagia: Approximately 10–15% of patients experience persistent dysphagia due to incomplete myotomy, fibrous healing, or progressive oesophageal dilation. Incomplete gastric extension of the myotomy (less than 2 cm onto the cardia) is the most common technical cause. Re-do myotomy, POEM, or repeated PD can be attempted for recurrence.

Fundoplication-Related Symptoms: Tight fundoplication may cause gas-bloat syndrome, inability to belch, or persistent dysphagia in 5–10% of patients. Slippage or herniation of the wrap is rare but requires surgical correction.

Aspiration and Pulmonary Complications: Pre-operative aspiration pneumonia occurs in up to 10% of patients with advanced achalasia and significant oesophageal dilation. Postoperative aspiration is rare after successful myotomy. Deep vein thrombosis and pulmonary embolism prophylaxis with LMWH are mandatory given laparoscopic surgery and pneumoperitoneum.

Structured follow-up after LHM ensures timely detection of treatment failure, GERD, and disease progression.

Immediate Postoperative Care: Patients are kept nil by mouth for 24–48 hours. A gastrografin swallow study is performed on postoperative day 1 to exclude mucosal perforation and assess free flow through the myotomised segment. Oral fluids are commenced and advanced to a soft diet by 48–72 hours. Hospital discharge is typically achieved by day 2–3. Patients should avoid solid food for 2 weeks to allow mucosal healing. Proton pump inhibitor (PPI) therapy is initiated post-operatively and continued for 3–6 months until ambulatory pH monitoring confirms adequate reflux control.

Symptom Monitoring: The Eckardt score is reassessed at 3 months, 1 year, and annually thereafter. Endoscopy is performed at 1–2 years to assess oesophagitis, mucosal healing, and the anastomotic region. Barium swallow at 3–6 months assesses oesophageal emptying and confirms myotomy adequacy (complete emptying within 1–2 minutes on timed barium swallow).

Ambulatory pH Monitoring: 24-hour oesophageal pH-impedance monitoring is performed at 3–6 months post-operatively (off PPI) to quantify acid reflux. DeMeester score and percentage total acid exposure time guide PPI dose adjustment. Patients with abnormal acid exposure require long-term PPI therapy; those with continued symptoms despite PPI may be candidates for fundoplication revision.

Long-Term Surveillance: Patients with achalasia have an approximately 10–20 fold increased lifetime risk of squamous cell carcinoma of the oesophagus compared to the general population (cumulative risk approximately 3–8% over 25 years). Surveillance endoscopy every 3–5 years starting 10–15 years after diagnosis is recommended by most guidelines, though formal national guidance varies. Patients with post-myotomy reflux and Barrett's oesophagus require more frequent endoscopic surveillance per Barrett's protocols.

The cost of laparoscopic Heller myotomy varies widely by country, reflecting differences in healthcare infrastructure, surgeon fees, operating room costs, and hospital stay duration.

United States and Western Europe: In the United States, LHM with fundoplication typically costs USD 25,000–50,000 including anaesthesia, surgeon fees, operative costs, and hospital stay (2–3 days). UK NHS patients receive treatment at no direct cost, but private surgery costs GBP 8,000–15,000. In Germany and France, costs range from EUR 8,000–20,000 in private settings.

Medical Tourism Destinations: India offers LHM at USD 3,000–6,000 at JCI-accredited centres in Delhi, Mumbai, Chennai, and Bengaluru, performed by surgeons with extensive experience in oesophageal surgery. Thailand (Bangkok, Chiang Mai) prices range from USD 5,000–10,000. Turkey charges USD 4,000–8,000. Mexico offers USD 6,000–12,000 at accredited centres near the US border (Monterrey, Tijuana). These represent savings of 60–80% compared to US prices.

POEM vs LHM Cost Comparison: POEM is increasingly offered at comparable cost to LHM at specialised endoscopy centres, though procedure costs vary by equipment (endoscopic submucosal dissection tools, CO2 insufflation). In India and Southeast Asia, POEM costs approximately USD 2,500–5,000 and avoids general surgical team requirements, making it competitive. The decision between POEM and LHM should be based on clinical criteria (achalasia subtype, GERD risk) rather than cost alone.

Additional Cost Factors: Pre-operative HRM ("gold standard" diagnostic test) costs USD 1,000–3,000 in Western countries but is available for USD 100–300 in India and Southeast Asia. Travel insurance, post-operative accommodation, and remote follow-up (video consultation) add USD 500–2,000 for international patients. Most reputable international centres provide coordinator support and telemedicine follow-up as part of surgical packages.

Three established therapeutic alternatives to LHM exist for achalasia, each with distinct indications, efficacy profiles, and risk characteristics.

Per-Oral Endoscopic Myotomy (POEM): POEM has become the main competitor to LHM at specialised centres. Advantages over LHM include: no abdominal incisions, the ability to extend the myotomy proximally (critical advantage in Type III achalasia), potential shorter hospital stay (1–2 days), and equivalence in functional outcomes at 2 years (iPoEM trial). The principal disadvantage is significantly higher post-procedural GERD (approximately 40–57% on pH monitoring), which mandates long-term PPI use and surveillance endoscopy in most patients. POEM is currently preferred by many centres for Type III achalasia and for re-do procedures after failed LHM.

Endoscopic Pneumatic Dilation (PD): PD involves fluoroscopy-guided balloon dilation of the LES using progressively sized balloons (30, 35, 40 mm — Rigiflex system, Microvasive/Boston Scientific). Three dilation sessions over 4–6 weeks (the "step-up" protocol) are required for optimal effect. Clinical success rates at 2 years are 75–90% for Type II achalasia. A landmark multicentre European RCT (Boeckxstaens et al., NEJM 2011) demonstrated equivalent 5-year success rates for PD and LHM in non-sigmoid achalasia (93% vs 90%). PD is particularly suitable for patients who decline surgery or have high anaesthetic risk. Oesophageal perforation occurs in approximately 1–3% of procedures and usually requires urgent surgical repair.

Botulinum Toxin Injection: Endoscopic injection of botulinum toxin into the LES achieves clinical remission in 65–70% of patients at 6 months, declining to 30–40% at 12 months due to toxin degradation. It does not prevent future surgical therapy. Its role is restricted to elderly patients (70+ years), frail patients with multiple comorbidities who cannot tolerate POEM, PD, or surgery, and as a temporising measure to improve nutrition before definitive therapy. Repeated injections are less effective than the initial procedure due to fibrosis.

Observation (Watchful Waiting): Not appropriate for symptomatic achalasia with Eckardt score ≥3, as untreated achalasia leads to progressive oesophageal dilation, malnutrition, aspiration, and markedly elevated oesophageal cancer risk. Very mild symptoms (Eckardt score 1–2) in elderly or high-risk patients may be managed conservatively with dietary modification (eat slowly, drink water after meals, avoid lying down after eating) while surveillance endoscopy monitors for mucosal complications.